The experimental antitumour properties of three congeners of the acridylmethanesulphonanilide (AMSA) series.
D000166:Acridines / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D000840:Anisoles / Q000008:administration & dosage / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D055598:Chemical Phenomena; D002627:Chemistry, Physical; D003561:Cytarabine / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D007271:Injections, Intradermal; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D007939:Leukemia L1210 / Q000188:drug therapy*; D007942:Leukemia, Experimental / Q000188:drug therapy; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy; D008545:Melanoma / Q000188:drug therapy; D051379:Mice; D008815:Mice, Inbred Strains; D009374:Neoplasms, Experimental / Q000188:drug therapy; D010655:Phenylenediamines / Q000008:administration & dosage / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000188:drug therapy; D013329:Structure-Activity Relationship; D013450:Sulfones / Q000008:administration & dosage / Q000627:therapeutic use
D000166:Acridines; D000840:Anisoles; D000970:Antineoplastic Agents; D010655:Phenylenediamines; D013450:Sulfones; D003561:Cytarabine